Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial

The Journal of Clinical Endocrinology & Metabolism(2024)10.1210/clinem/dgae522Source: DataRank Database

Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial is a research paper published in The Journal of Clinical Endocrinology & Metabolism (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 0.89)OA: greenTopics (64)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Christine Newman ORCID,Alberto Alvarez‐Iglesias ORCID,Paula O’Shea ORCID,Declan Devane ORCID,Paddy Gillespie ORCID

Live enrichment

PubMed:39056256 PMC:PMC12168073 OpenAlex:https://openalex.org/W4401033613

NIDDK NIH HHS

Grant: K23 DK134767

Health Research Board

Grant: unidentified

unidentified

HRB-Clinical Research Facility Galway

Ascensia

Health Research Board of Ireland

Merck Healthcare KGaA

NIH

HRB

Health Research Board of Ireland

HRB

HRB-Clinical Research Facility Galway

Merck Healthcare KGaA

Ascensia

FWCI

0.89

Citation Percentile

0.7%

Citation Trend

2025

greenLicense: OUP Standard Publication Reuse

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12168073

publisherhttps://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae522/58757599/dgae522.pdf

publisherhttps://academic.oup.com/jcem/article-pdf/110/5/e1566/58757599/dgae522.pdf

journalhttps://doi.org/10.1210/clinem/dgae522

Fields of Study

Gestational Diabetes Research and ManagementPregnancy and preeclampsia studiesBirth, Development, and Health03 medical and health sciences0302 clinical medicineAdultFemaleHumansPregnancyBlood GlucoseBlood PressureBody Mass IndexCardiometabolic Risk FactorsDiabetes, GestationalDouble-Blind MethodHypoglycemic AgentsMetforminPostpartum PeriodSecondary Data AnalysisRandomized Controlled Trials as Topic

MeSH Terms

Cardiometabolic Risk FactorsSecondary Data AnalysisAdultBlood GlucoseBlood PressureDouble-Blind MethodFemaleHumansHypoglycemic AgentsMetforminPregnancyBody Mass IndexRandomized Controlled Trials as TopicDiabetes, GestationalPostpartum Period

Keywords

MedicineMetforminGestational diabetesPlaceboBody mass indexObstetricsWaistPrediabetesDiabetes mellitusInsulin resistancePregnancyType 2 diabetesInternal medicinePostpartum periodInsulinEndocrinologyGestationPostpartum HealthAdultBlood GlucoseCardiometabolic Risk FactorsBlood PressureDiabetes, GestationalSecondary Data AnalysisDouble-Blind MethodHumansHypoglycemic AgentsFemaleRandomized Controlled Trials as Topic

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being

Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial

FAIR Checklist

Authors (9)

Funding (13 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)